“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th U.S. Surgeon General Richard Carmona
25.1.2021 16:00:00 EET | Business Wire | Press release
As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/
WELL Health-Safety Seal (Photo: Business Wire)
This national advertising campaign, a first from the International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, explains the importance of health and safety through building design and operations as well as organizational policy, and sheds light on what the featured ambassadors have missed most during the pandemic. From Jennifer Lopez’s family movie nights to Robert DeNiro missing a “variety in existence,” each of these cultural influencers are feeling the longing for shared connection as much as the rest of us, even beyond the changes to their respective industries and day-to-day lives.
“This is more than an awareness campaign; it’s meant to ignite a movement. These ambassadors and cultural influencers are partnering with us because they truly believe in the mission – and how critical it is – to make buildings and shared spaces center on health going forward,” said Paul Scialla, Founder of the International WELL Building Institute and CEO of its parent company, Delos. “To succeed at scale means we are improving indoor spaces to help ensure that the people who visit them can be healthier and safer. This is a win for everyone involved.”
The WELL Health-Safety Rating brings together building expertise and nearly a decade of health science to promote indoor safety, creating an efficient and cost-effective opportunity to guide, validate, recognize and scale efforts to manage critical health and safety issues in shared spaces. The WELL Health-Safety Rating examines 22 features across five core areas – Cleaning and Sanitization Procedures, Emergency Preparedness Programs, Health Service Resources, Air and Water Quality Management, and Stakeholder Engagement and Communication – and requires a minimum of 15 criteria be met in order to achieve the rating and be awarded the WELL Health-Safety seal.
As such, the seal is a symbol of trust and confidence that is backed by science, structure and, most importantly, third-party verification. IWBI has seen thousands of buildings enroll in the program since its launch in July 2020, and expects significant global adoption to continue in 2021 and beyond.
“While the WELL Health-Safety Rating was a response to this moment in time, it was developed to address broader health and safety-related issues well into the future,” said Rachel Hodgdon, President and CEO of the International WELL Building Institute. “We collaborated with our global community to create something that’s flexible for all building types and organizational priorities. This consistency across market sectors means people will see the seal at their favorite restaurants, stadiums and hotels, and at their office, childcare center or college campus and know it stands for the same thing in every location, that science-based strategies have been implemented and safety has been prioritized.”
The WELL Health-Safety Rating was developed in response to market demand and informed by IWBI’s Task Force on COVID-19, which included nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals. More than 1.5 billion square feet of space are enrolled in WELL offerings. To date, Yankee Stadium, the Empire State Building, JPMorgan Chase, RocketMortgage Field House, Amalie Arena, Spectrum Center, Simon Property Group, BB&T Center, Aimbridge Hospitality and AT&T Stadium, among others, have achieved the WELL Health-Safety Rating.
The public awareness campaign launched today and comes to life through TV, digital video and social advertising. TV commercials will appear nationally through early spring 2021. The campaign creative was developed by advertising agency SWAT by Kirshenbaum, directed by Spike Lee and produced by Pony Show Entertainment.
“From an enterprise standpoint, this is an exceptionally exciting time for all of us,” said Delos CMO Anthony Antolino. “Helping everyone to get back to business with confidence is critical, and these celebrity ambassadors are key in helping spread the word.”
For more information about the campaign, please visit www.WellHealthSafety.com.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. The WELL Building Standard anchors a WELL ecosystem that includes WELL v2, the WELL Community Standard, the WELL Health-Safety Rating and WELL Accredited Professionals. IWBI mobilizes its community through the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and well-being for everyone, everywhere. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating, WE ARE WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005216/en/
Contact information
Samantha Wolf
Tel. 646-935-4032
samantha.wolf@ketchum.com
Jamie Matos
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
